Company Filing History:
Years Active: 2023
Title: Emma Hajaj: Innovator in Cancer Immunotherapy
Introduction
Emma Hajaj is a prominent inventor based in Netanya, Israel. She has made significant contributions to the field of cancer immunotherapy, focusing on innovative therapeutic modalities. Her work aims to improve treatment options for cancer patients through advanced scientific research.
Latest Patents
Emma Hajaj holds a patent titled "Modulation of SLAMF6 splice variants for cancer therapy." This invention relates to cancer immunotherapy, particularly to improved therapeutic modalities involving the specific modulation of the expression and/or activity of SLAMF6 splice variants. The patent outlines compositions and methods for cancer therapy, including adoptive T cell transfer therapies, cell vaccines, and polypeptide-based medicaments. Notably, the invention provides methods for selectively augmenting SLAMF6 variant 3 expression or activity on T cells and/or tumor cells.
Career Highlights
Emma Hajaj is associated with Hadasit Medical Research Services and Development Ltd., where she continues her research and development efforts. Her work has garnered attention for its potential to enhance cancer treatment strategies and improve patient outcomes.
Collaborations
Emma collaborates with esteemed colleagues, including Michal Lotem and Galit Mishan Eisenberg. These partnerships contribute to the advancement of her research and the development of innovative cancer therapies.
Conclusion
Emma Hajaj is a trailblazer in the field of cancer immunotherapy, with a focus on innovative approaches to treatment. Her patent and collaborative efforts reflect her commitment to advancing medical science and improving the lives of cancer patients.